Online citations, reference lists, and bibliographies.
← Back to Search

Traitement Du Mésothéliome Pleural Malin En 2016

A. Scherpereel
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Resume Introduction Le mesotheliome pleural malin (MPM) est un cancer assez rare, de mauvais pronostic, le plus souvent secondaire a une exposition a l’amiante. Etat des connaissances : Il n’y a pas de traitement curatif valide a ce jour. De rares patients tres selectionnes sont de potentiels candidats a une chirurgie « radicale » et un traitement multimodal, non valide en routine. La chimiotherapie par le doublet cisplatine et pemetrexed, est le traitement standard en premiere ligne mais peu efficace. Perspectives Neanmoins, le recent congres mondial 2016 de l’international Mesothelioma interest group (iMig) a permis de souligner les resultats tres prometteurs de nouveaux traitements et strategies therapeutiques. De multiples essais cliniques innovants sont aussi en cours ou prevus, pouvant combiner la chimiotherapie standard, diverses immunotherapies antitumorales, des therapies ciblees ou encore une pleurectomie/decortication etendue (eP/D), une chirurgie d’exerese tumorale maximale macroscopique du MPM. Conclusions La France participe largement a l’evaluation de ces nouveaux differents traitements et strategies par des essais cliniques prospectifs multicentriques (essai MAPS-2 de l’IFCT…), favorisee par le reseau national clinique des centres experts du MPM, appele « MESOCLIN », en lien avec les associations de patients.
This paper references
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1200/JCO.2012.30.15_SUPPL.7030
Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial.
R. Hassan (2012)
10.1183/09031936.00037310
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
10.1016/S0003-4975(98)00799-1
Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up.
T. L. Moskal (1998)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1183/09031936.00207213
Multimodal management of malignant pleural mesothelioma: where are we today?
P. V. Van Schil (2014)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1158/0008-5472.CAN-07-6265
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
A. Gauvrit (2008)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1016/j.ejca.2013.05.008
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
M. O'Brien (2013)
10.1097/JTO.0000000000000064
Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients
P. Bovolato (2014)
10.2174/1871520611313020014
The role of mesothelin in tumor progression and targeted therapy.
Zhewei Tang (2013)
[The experts' conference of the Société de Pneumologie de Langue Française (SPLF) on malignant pleural mesothelioma (MPM): useful and necessary recommendations].
A. Scherpereel (2006)
10.5306/wjco.v7.i2.135
Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
I. Marchesi (2016)
10.1126/scitranslmed.3006941
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
R. Hassan (2013)
10.1136/bmjopen-2014-006673
Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases
A. Clive (2015)
10.1158/1078-0432.CCR-09-0062
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
R. Kreitman (2009)
10.1097/JTO.0b013e318260dfb9
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
D. Fennell (2012)
10.1016/S0959-8049(11)70098-3
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
L. Krug (2011)
10.4161/onci.27482
Immune checkpoint blockade in malignant mesothelioma
L. Calabrò (2014)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1097/JTO.0b013e318191520c
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
S. Ramalingam (2009)
10.1016/J.PNEUMO.2010.07.013
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)
10.1097/JTO.0000000000000083
Comparative Outcomes of Elderly Stage I Lung Cancer Patients Treated with Segmentectomy via Video-Assisted Thoracoscopic Surgery versus Open Resection
C. Smith (2014)
10.1016/j.athoracsur.2014.05.071
Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions.
O. Lauk (2014)
10.1097/COC.0b013e3181cae90e
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study
Ioannis S Tourkantonis (2011)
10.1038/nm.3947
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1007/BF02303538
Intrapleural photodynamic therapy: Results of a phase I trial
H. Pass (2006)
10.1016/j.jtcvs.2012.12.037
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
10.1200/JCO.2012.42.1784
Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.
P. Szlosarek (2013)
10.1158/1078-0432.CCR-10-2275
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1126/scitranslmed.3008639
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
I. Shapiro (2014)
10.1016/S1470-2045(11)70307-2
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1016/j.lungcan.2013.11.004
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
N. Macleod (2014)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1002/cncr.28875
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
R. Hassan (2014)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1200/JCO.2003.05.123
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.3978/j.issn.2225-319X.2012.11.14
Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma.
J. Friedberg (2012)
10.1016/0003-4975(94)90443-X
Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study.
H. Takita (1994)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1093/ANNONC/MDI187
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
10.1016/j.lungcan.2013.05.006
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
A. Nowak (2013)
10.1158/1078-0432.CCR-15-2133
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
D. Sterman (2016)
10.3816/CLC.2010.n.005
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
10.1016/J.LUNGCAN.2004.08.005
Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
D. Fennell (2005)
10.1016/j.jtcvs.2014.03.011
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
B. Burt (2014)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1016/j.athoracsur.2011.02.062
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.
J. Friedberg (2011)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.3978/j.issn.2072-1439.2014.05.03
Management of malignant pleural mesothelioma-The European experience.
I. Opitz (2014)
10.1158/0008-5472.CAN-14-1328
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1158/1078-0432.CCR-11-2121
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
D. Le (2011)
10.1164/rccm.201508-1573OC
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
R. Cornelissen (2016)



Semantic Scholar Logo Some data provided by SemanticScholar